This inventor holds 2 USPTO granted patents and 2 published patent applications and 1 EPO patent. Top assignees: Ascentage Pharma (Suzhou) Co., Ltd., Ascentage Pharma Group Corp Limited. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
2 out of 10 
2 out of 29 Years Active: 2026
Title: Jianyong Chen - Innovator in Pharmaceutical Research
Introduction
Jianyong Chen is a notable inventor based in Suzhou, China. He has made significant contributions to the field of pharmaceutical research, particularly in the development of compounds that target specific proteins involved in various diseases. Although he currently holds no granted patents, his work is poised to impact the medical community.
Latest Patent Applications
Jianyong Chen's latest patent applications include:
1. **KRAS Inhibitors** - The present disclosure relates to compounds that inhibit KRAS. In particular, the present disclosure relates to compounds that inhibit the activity of KRAS G12D, pharmaceutical compositions comprising the compounds, and methods of use therefor.
2. **Sulfonyl Benzamide Derivatives as BCL-2 Inhibitors** - The present disclosure provides compounds having Formula I and the pharmaceutically acceptable salts and solvates thereof, wherein variables are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I for use to treat a disease, disorder, or condition responsive to Bcl-2 protein inhibition, particularly Bcl-2 WT and/or Bcl-2 G101V.
Conclusion
Jianyong Chen is an emerging inventor whose research in pharmaceutical compounds holds promise for future medical advancements. His innovative approaches to targeting KRAS and BCL-2 proteins may lead to significant breakthroughs in treatment options.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile